Aldeyra Therapeutics, Inc. (ALDX)
Company Info
Highlights
$167.78M
-$0.94
$244.53K
$182.90K
-$46.15M
$1.14 - $7.20
$8.29
8.68%
1.36
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Aldeyra Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Aldeyra Therapeutics, Inc. (ALDX) returned -59.72% year-to-date (YTD) and -51.80% over the past 12 months. Over the past 10 years, ALDX returned -12.43% annually, underperforming the S&P 500 benchmark at 10.31%.
ALDX
-59.72%
3.08%
-62.78%
-51.80%
-6.77%
-12.43%
^GSPC (Benchmark)
-4.26%
11.24%
-5.02%
8.55%
14.02%
10.31%
Monthly Returns
The table below presents the monthly returns of ALDX, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 5.01% | -2.48% | 12.52% | -53.91% | -24.15% | -59.72% | |||||||
| 2024 | -10.83% | 15.65% | -9.67% | 20.49% | -2.03% | -14.25% | 19.03% | 46.07% | -6.34% | -2.41% | -6.84% | 1.84% | 42.17% |
| 2023 | -15.23% | 14.58% | 46.89% | -4.03% | -0.42% | -11.59% | -3.28% | -8.07% | -10.46% | -74.40% | 61.99% | 26.71% | -49.57% |
| 2022 | -8.25% | 10.08% | 10.02% | -30.93% | 0.65% | 29.13% | 26.32% | 39.68% | -24.15% | 2.25% | 2.56% | 24.29% | 74.00% |
| 2021 | 63.27% | 9.46% | -3.10% | 5.81% | -0.40% | -9.50% | -21.45% | 6.63% | -7.48% | 3.64% | -15.71% | -47.85% | -41.69% |
| 2020 | -8.09% | -28.84% | -35.00% | 27.53% | 56.19% | -15.24% | 54.20% | 1.56% | 13.48% | -9.85% | 5.24% | -2.42% | 18.07% |
| 2019 | 6.14% | -8.29% | 11.76% | -8.42% | -15.72% | -13.92% | -8.67% | -19.53% | 19.50% | 6.07% | 42.75% | -27.19% | -30.00% |
| 2018 | 9.93% | 10.37% | -9.09% | 4.67% | 7.01% | -5.36% | -12.58% | 21.58% | 63.31% | -21.96% | -16.71% | -7.47% | 22.06% |
| 2017 | 1.87% | -9.17% | 1.01% | -13.00% | 16.09% | -7.92% | 2.15% | -12.63% | 73.49% | -12.50% | 5.56% | 2.26% | 27.10% |
| 2016 | -29.06% | 1.87% | -14.49% | 50.36% | -7.78% | -2.07% | 8.08% | -9.92% | 41.16% | -32.86% | -1.90% | 3.88% | -21.09% |
| 2015 | 67.59% | -15.70% | -0.20% | -7.24% | -21.11% | 4.16% | 14.56% | -18.79% | -19.25% | 18.01% | 5.81% | -6.87% | -6.09% |
| 2014 | -15.24% | 7.49% | -45.58% | -3.08% | 71.10% | 16.55% | 4.64% | -0.00% | 0.28% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of ALDX is 27, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Aldeyra Therapeutics, Inc. (ALDX) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the Aldeyra Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Aldeyra Therapeutics, Inc. was 90.44%, occurring on Apr 3, 2025. The portfolio has not yet recovered.
The current Aldeyra Therapeutics, Inc. drawdown is 86.46%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -90.44% | Apr 28, 2021 | 989 | Apr 3, 2025 | — | — | — |
| -88.71% | Sep 28, 2018 | 367 | Mar 16, 2020 | 232 | Feb 16, 2021 | 599 |
| -70.91% | Feb 2, 2015 | 267 | Feb 24, 2016 | 652 | Sep 26, 2018 | 919 |
| -56.32% | Jun 20, 2014 | 31 | Aug 5, 2014 | 54 | Oct 21, 2014 | 85 |
| -31.86% | Oct 30, 2014 | 39 | Dec 26, 2014 | 14 | Jan 16, 2015 | 53 |
Volatility
Volatility Chart
The current Aldeyra Therapeutics, Inc. volatility is 34.20%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Aldeyra Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Aldeyra Therapeutics, Inc., comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -24.3%.
Valuation
The Valuation section provides an overview of how Aldeyra Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for ALDX compared to other companies in the Biotechnology industry. ALDX currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for ALDX relative to other companies in the Biotechnology industry. Currently, ALDX has a P/S ratio of 0.0. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ALDX in comparison with other companies in the Biotechnology industry. Currently, ALDX has a P/B value of 2.4. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |